Tag: nach dave

Clinical Research: Phase 1 - Phase 4

PharmaVoice – Small Pharma Driving Big Pharma Innovation

“Big pharma’s new role in this is to partner and fund the innovation that it so sorely needs to bulk up its dwindling pipelines. This is a cost-effective move for larger drug companies to leverage outside scientific talent to gain access to breakthrough discoveries. “‘This is a dominant trend in the industry,’ says Nach Davé,...

Clinical Research: Phase 1 - Phase 4

Are We Trading Speed for Innovation in Approving New Drugs?

DURHAM, N.C., February 16, 2018 — Are expedited approvals of new drugs occurring at the expense of innovation? Nach Davé, Vice President of Global Regulatory Affairs at Premier Research, will explore the subject at Outsourcing in Clinical Trials West Coast 2018, February 21 in Burlingame, California. In his presentation, Faster Approvals but Less Innovation: Trend...

Medical and Regulatory Affairs

Premier Research Names Nach Davé VP of Global Regulatory Affairs

DURHAM, N.C., August 7, 2017 — Premier Research announces the appointment of Nach Davé, RPh, MS, as Vice President of Global Regulatory Affairs. He oversees the company’s regulatory affairs service offerings in rare diseases and across its broad range of therapeutic focus areas, bringing to the position more than 20 years of experience in the...